Eiger BioPharmaceuticals is a clinical-stage biopharmaceutical company focused on developing innovative therapies for rare metabolic diseases. Based in Palo Alto, United States, the company specializes in creating treatments for orphan diseases, addressing unmet medical needs in the healthcare sector. Eiger's primary mission is to advance novel drugs and therapies through clinical trials to improve the lives of patients with rare conditions.

The company has made significant strides in its research and development efforts, particularly with its drug Zokinvy® (Lonafarnib) for the treatment of Hutchinson-Gilford Progeria Syndrome. Eiger has also been working on treatments for hepatitis delta virus (HDV) and other metabolic disorders. Under new leadership, the company has refocused its efforts on metabolic diseases, with a particular emphasis on developing avexitide, demonstrating its commitment to addressing critical areas of medical need.